Literature DB >> 33975857

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.

Robert Spiera1,2, Sarah Jinich3, Deanna Jannat-Khah3,2.   

Abstract

Entities:  

Keywords:  COVID-19; antirheumatic agents; rituximab; vaccination

Year:  2021        PMID： 33975857     DOI： 10.1136/annrheumdis-2021-220604

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  52 in total

1.  Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

2.  Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273.

Authors:  Ruth R Hagen; Jet van den Dijssel; Lisan H Kuijper; Christine Kreher; Thomas Ashhurst; S Marieke van Ham; Anja Ten Brinke; Carolien E van de Sandt; Niels J M Verstegen; Laura Y L Kummer; Maurice Steenhuis; Mariel Duurland; Rivka de Jongh; Nina de Jong; C Ellen van der Schoot; Amélie V Bos; Erik Mul; Katherine Kedzierska; Koos P J van Dam; Eileen W Stalman; Laura Boekel; Gertjan Wolbink; Sander W Tas; Joep Killestein; Zoé L E van Kempen; Luuk Wieske; Taco W Kuijpers; Filip Eftimov; Theo Rispens
Journal:  Elife       Date:  2022-07-15       Impact factor: 8.713

3. 

Authors:  Maxime Auroux; Benjamin Laurent; Baptiste Coste; Emmanuel Massy; Alexandre Mercier; Isabelle Durieu; Cyrille B Confavreux; Jean-Christophe Lega; Sabine Mainbourg; Fabienne Coury
Journal:  Rev Rhum Ed Fr       Date:  2022-07-08

4.  Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab.

Authors:  Victoria Furer; Tali Eviatar; Devy Zisman; Hagit Peleg; Yolanda Braun-Moscovici; Alexandra Balbir-Gurman; Daphna Paran; David Levartovsky; Michael Zisapel; Ofir Elalouf; Ilana Kaufman; Adi Broyde; Ari Polachek; Joy Feld; Amir Haddad; Tal Gazitt; Muna Elias; Nizar Higazi; Fadi Kharouf; Sara Pel; Sharon Nevo; Ori Elkayam
Journal:  Vaccines (Basel)       Date:  2022-06-06

5.  Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort.

Authors:  Daniele Mauro; Antonio Ciancio; Claudio Di Vico; Luana Passariello; Gelsomina Rozza; Maria Dora Pasquale; Ilenia Pantano; Carlo Cannistrà; Laura Bucci; Silvia Scriffignano; Flavia Riccio; Martina Patrone; Giuseppe Scalise; Piero Ruscitti; Maria Vittoria Montemurro; Antonio Giordano; Maria Teresa Vietri; Francesco Ciccia
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

6.  Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2021-11-18       Impact factor: 5.732

7.  Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.

Authors:  Giacomo Malipiero; Anna Moratto; Maria Infantino; Pierlanfranco D'Agaro; Elisa Piscianz; Mariangela Manfredi; Valentina Grossi; Enrico Benvenuti; Matteo Bulgaresi; Maurizio Benucci; Danilo Villalta
Journal:  Immunol Res       Date:  2021-08-21       Impact factor: 4.505

8.  Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.

Authors:  Laura Boekel; Maurice Steenhuis; Femke Hooijberg; Yaëlle R Besten; Zoé L E van Kempen; Laura Y Kummer; Koos P J van Dam; Eileen W Stalman; Erik H Vogelzang; Olvi Cristianawati; Sofie Keijzer; Gestur Vidarsson; Alexandre E Voskuyl; Luuk Wieske; Filip Eftimov; Ronald van Vollenhoven; Taco W Kuijpers; S Marieke van Ham; Sander W Tas; Joep Killestein; Maarten Boers; Michael T Nurmohamed; Theo Rispens; Gertjan Wolbink
Journal:  Lancet Rheumatol       Date:  2021-08-06

9.  SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.

Authors:  Daniel Mrak; Selma Tobudic; Maximilian Koblischke; Marianne Graninger; Helga Radner; Daniela Sieghart; Philipp Hofer; Thomas Perkmann; Helmuth Haslacher; Renate Thalhammer; Stefan Winkler; Stephan Blüml; Karin Stiasny; Judith H Aberle; Josef S Smolen; Leonhard X Heinz; Daniel Aletaha; Michael Bonelli
Journal:  Ann Rheum Dis       Date:  2021-07-20       Impact factor: 19.103

10.  Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.

Authors:  Edward J Carr; Andreas Kronbichler; Matthew Graham-Brown; Graham Abra; Christos Argyropoulos; Lorraine Harper; Edgar V Lerma; Rita S Suri; Joel Topf; Michelle Willicombe; Swapnil Hiremath
Journal:  Kidney Int Rep       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.